This is a follow-up study to our previous analysis of thyroid aspirates utilizing the Bethesda System for Reporting Thyroid Cytology (BSRTC). The same study design was utilized for 2 years comparing 2 periods. A total of 251 thyroid aspirates from 218 patients were reviewed and deemed comparable to the previous cohort. The variance and consequently the number of interpretations dropped from 26 to 11 with a statistically significant 58% reduction and more consistency. Our unsatisfactory rate dropped from 22 to 10% (reduction of 55%). The risk of malignancy in this follow-up study showed a similar trend: an increase in risk with each step up in the BSRTC categories starting from the ‘nondiagnostic' and up to ‘malignant'. Few of our benign cases ended up with resection. We noticed sensitivity to the word ‘follicular' in this benign category; therefore we propose a modification of the current BSRTC system by omitting the word ‘follicular' from the benign category. We strongly believe that this modification harbors no serious damage to the intentions of BSRTC. This follow-up study has shown that the previous awareness campaign about the implementation has worked and can be considered a valid performance improvement program.

Hassell LA, Gillies EM, Dunn ST: Cytologic and molecular diagnosis of thyroid cancers: is it time for routine reflex testing? Cancer Cytopathol 2012;120:7-17.
Vojvodich SM, Ballagh RH, Cramer H, Lampe HB: Accuracy of fine needle aspiration in the pre-operative diagnosis of thyroid neoplasia. J Otolaryngol 1994;23:360-365.
Ko HM, Jhu IK, Yang SH, Lee JH, Nam JH, Juhng SW, Choi C: Clinicopathologic analysis of fine needle aspiration cytology of the thyroid. A review of 1,613 cases and correlation with histopathologic diagnosis. Acta Cytol 2003;47:727-732.
Ali SZ, Cibas ES: The Bethesda System for Reporting Thyroid Cytopathology. Definitions, Criteria and Explanatory Notes. New York, Springer, 2010.
Al-Abbadi MA, Shareef SQ, Ali JA, Yousef MM: Application of the Bethesda System for Reporting Thyroid Cytopathology in the Eastern Province of Saudi Arabia: phase I pilot retrospective analysis. Acta Cytol 2013;57:481-488.
Layfield LJ, Cibas ES, Gharib H, Mandel SJ: Thyroid aspiration cytology: current status. CA Cancer J Clin 2009;59:99-110.
Al-Shraim MM, Kaood OM, Hussain MR, Al-Ahmary AM, Al-Shehri GY, Jastania RA, Mahfouz AA, Abu-Eshy SA: Assessment of malignancy rate in thyroid nodules according to the Bethesda system of fine-needle aspiration. Saudi Med 2012;2:167-171.
Sebo TJ: What are the keys to successful thyroid FNA interpretation? Clin Endocrinol (Oxf) 2012;77:13-17.
Cibas ES: Fine-needle aspiration in the work-up of thyroid nodules. Otolaryngol Clin North Am 2010;43:257-271.
El Hag IA, Kollur SM, Chiedozi LC: The role of FNA in the initial management of thyroid lesions: 7-year experience in a district general hospital. Cytopathology 2003;14:126-130.
Ylagan LR, Farkas T, Dehner LP: Fine needle aspiration of the thyroid: a cytohistologic correlation and study of discrepant cases. Thyroid 2004;14:35-41.
De Vos tot Nederveen Cappel RJ, Bouvy ND, Bonjer HJ, van Muiswinkle JM, Chadha S: Fine needle aspiration of the thyroid nodules: how accurate is it and what are the causes of discrepant cases? Cytopathology 2001;12:399-405.
Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC: The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 2009;19:1215-1223.
Her-Juing Wu H, Rose C, Elsheikh TM, The Bethesda system for reporting thyroid cytopathology: an experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol 2012;40:399-403.
Ali SZ: Thyroid cytopathology: Bethesda and beyond. Acta Cytol 2011;55:4-12.
Sullivan PS, Hirschowitz SL, Fung PC, Apple SK: The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System. Cancer Cytopathol 2014;122:866-872.
Srbova L, Gabalec F, Ryska A, Cap J: Results of retrospective classification of thyroid FNAs according to the Bethesda system: would this have improved accuracy? Cytopathology, Epub ahead of print.
McElroy MK, Mahooti S, Hasteh F: A single institution experience with the new Bethesda system for reporting thyroid cytopathology: correlation with existing cytologic, clinical, and histological data. Diagn Cytopathol 2014;42:564-569.
Ustün H, Astarcı HM, Altunkaya C, Yılmaz S, Barın A, Ekici S, Caydere M: Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to thyroid Bethesda system. Acta Cytol 2012;56:361-369.
Singh RS, Wang HH: Timing of repeat thyroid fine-needle aspiration in the management of thyroid nodules. Acta Cytol 2011;55:544-548.
Gocun PU, Karakus E, Bulutay P, Akturk M, Akin M, Poyraz A: What is the malignancy risk for atypia of undetermined significance? Three years' experience at a university hospital in Turkey. Cancer Cytopathol 2014;122:604-610.
Vivero M, Renshaw AA, Krane JF: Influence of descriptive terminology on management of atypical thyroid fine-needle aspirates. Cancer Cytopathol 2014;122:175-181.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.